 |
|
Researchers uncover approach for possibly eradicating HIV infection
June 22, 2009ST. LUCIE, FL - Researchers from the newly-established VGTI Florida and the University of Montreal have uncovered a possible method for eradicating HIV infection in the human body. The researchers have also revealed new information which demonstrates how HIV persists in the body - even in patients receiving drug treatments - and how the virus continues to replicate itself in individuals undergoing treatment. The research findings will be published in the online version of the journal Nature Medicine on June 21 and will be featured in an upcoming print edition of the journal.
Medical advancements in the past 20 years have significantly increased the survival rates of AIDS patients. In fact, approximately 90 percent of patients infected with AIDS can survive with the disease as long as they are treated with a complex series of antiretroviral drugs.
"Current medications allow us to control HIV and limit its progression in most cases," explained Rafick-Pierre Sékaly, Ph.D., current scientific director for VGTI Florida, a former scientist at the University of Montreal, and senior author of the research paper. "However, the medications do not eradicate the disease. Instead, the disease persists within the body - much like water in a reservoir - and is never fully destroyed. We believe our latest research may help scientists and physicians overcome this hurdle."
The research team was able to identify a possible new way of attacking HIV by first identifying the specific cells where HIV infection persists in patients currently undergoing treatment. They found that the disease is able to survive within two subsets of memory T-cells. Memory T-cells are a portion of the body's immune system and have the ability to learn, detect and attack certain types of infectious diseases.
By infecting cells within the body's own immune system, HIV is able to avoid antiviral treatments that are effective in stopping HIV in other cell types in the body. In-effect, HIV uses the body's own defense system as a hideout.
The research team was also successful in identifying how these HIV-infected memory T-cells replenish themselves. When populating T-cells, HIV does not replicate itself as it does in other cell types on the body. Instead, HIV persists in memory T-cells through cell division - a finding that holds significant implications for possibly stopping the disease.
"Based on this research, we believe one possible method for eliminating HIV in the body is to use a combined approach," said Dr. Sékaly. "We propose the use of medications that target viral replication of HIV throughout the body, in combination with drugs that prevent infected memory T-cells from dividing. We believe that by attacking the disease in these distinct two ways at once for an extended period of time, we can eliminate the reservoirs of HIV that currently persist within the human body, leaving an individual disease-free."
The next step for researchers is to begin testing their proposed treatment method using animal models and newly developed therapies.
"While this is a preliminary finding, we are hopeful that this research discovery will guide us in eradicating HIV infection in the body," said Dr. Sékaly.
Oregon Health & Science University
The research team was able to identify a possible new way of attacking HIV by first identifying the specific cells where HIV infection persists in patients currently undergoing treatment. They found that the disease is able to survive within two subsets of memory T-cells. Memory T-cells are a portion of the body's immune system and have the ability to learn, detect and attack certain types of infectious diseases.
By infecting cells within the body's own immune system, HIV is able to avoid antiviral treatments that are effective in stopping HIV in other cell types in the body. In-effect, HIV uses the body's own defense system as a hideout.
The research team was also successful in identifying how these HIV-infected memory T-cells replenish themselves. When populating T-cells, HIV does not replicate itself as it does in other cell types on the body. Instead, HIV persists in memory T-cells through cell division - a finding that holds significant implications for possibly stopping the disease.
"Based on this research, we believe one possible method for eliminating HIV in the body is to use a combined approach," said Dr. Sékaly. "We propose the use of medications that target viral replication of HIV throughout the body, in combination with drugs that prevent infected memory T-cells from dividing. We believe that by attacking the disease in these distinct two ways at once for an extended period of time, we can eliminate the reservoirs of HIV that currently persist within the human body, leaving an individual disease-free."
The next step for researchers is to begin testing their proposed treatment method using animal models and newly developed therapies.
"While this is a preliminary finding, we are hopeful that this research discovery will guide us in eradicating HIV infection in the body," said Dr. Sékaly.
Oregon Health & Science University
HIV Infection Current Events and HIV Infection News RSSGlobal challenges and opportunities in fighting HIV/AIDS and neglected diseases
Responding to the HIV/AIDS pandemic and tackling so-called neglected tropical diseases are the focus of the November/December 2009 edition of Health Affairs.
HIV care providers applaud Congress' extension of Ryan White program
Medical providers on the front lines of HIV care applaud the U.S. Congress for extending the Ryan White HIV/AIDS Program, helping to ensure that more than half a million low-income, uninsured, or underinsured people living with HIV/AIDS have access to lifesaving care.
Pitt researchers find candidates for new HIV drugs
While studying an HIV protein that plays an essential role in AIDS progression, researchers at the University of Pittsburgh School of Medicine have discovered compounds that show promise as novel treatments for the disease.
NIH launches 2009 H1N1 influenza vaccine trials in HIV-infected pregnant women
The first clinical trials to test whether the 2009 H1N1 influenza vaccine can safely elicit a protective immune response in pregnant women launched yesterday, and a trial to conduct the same test in HIV-infected children and youth will begin next week.
Continuing racial differences in HIV prevalence in US
HIV prevalence among African Americans is ten times greater than the prevalence among whites. This racial disparity in HIV prevalence has persisted in the face of both governmental and private actions, involving many billions of dollars, to combat HIV.
HIV vaccine regimen demonstrates modest preventive effect in Thailand clinical study
In an encouraging development, an investigational vaccine regimen has been shown to be well-tolerated and to have a modest effect in preventing HIV infection in a clinical trial involving more than 16,000 adult participants in Thailand.
New chemically-activated antigen could expedite development of HIV vaccine
Scientists working to develop a vaccine for the human immunodeficiency virus (HIV) report they have created the first antigen that induces protective antibodies capable of blocking infection of human cells by genetically-diverse strains of HIV.
HIV uses several strategies to escape immune pressure
A study of how HIV mutates in response to immune system pressure by Emory Vaccine Center researchers shows that the virus can take several escape routes, not one preferred route.
New WHO data underscores global threat of the world's leading child killer
New World Health Organization data to be published in this week's edition of the Lancet will shed new light on two leading causes of pneumonia, the world's leading killer of children under age 5, both globally and within specific countries.
Making bacteria make useful proteins
By adapting a single protein on the surface of the bacterium Caulobacter crescentus, researchers at the University of British Columbia have turned it into a protein production factory, making useful proteins that can act as vaccines and drugs.
More HIV Infection Current Events and HIV Infection News Articles
 |
Teenagers, HIV, and AIDS: Insights from Youths Living with the Virus (Sex, Love, and Psychology) by Maureen E. Lyon (Editor), Lawrence J. D'Angelo (Editor) Who will want me now? It's a heart-wrenching question for teenagers infected with HIV. The number of HIV/AIDS-infected teenagers in the United States is increasing. Nearly 35,000 U.S. teenagers now have AIDS. Far more have been diagnosed with HIV, and an undetermined number have the virus and do not yet know. Each year, some 1,700 young people aged 13 to 24 are diagnosed with the ravaging end result of this infection: AIDS. In this volume, experts who work with HIV/AIDS-infected teenagers examine the psychological and social fallout compounding the frightening medical issues faced by adolescents who've received the diagnosis. Readers share the challenge with teens as they face the stigma of HIV/AIDS and the tough decisions about who to tell of their infection and when to do it. We learn... |
 |
Bile Salts by The Wolfe Clinic Bile salts are steroids with detergent properties, which are used to emulsify lipids in food passing through the intestine to enable fat digestion and absorption through the intestinal wall. They breakdown saturated fats into unsaturated fats, leading to the direct production of hormones. |
 |
The HIV / HCV Co-Infection Awareness Ribbon Mouse Pad by MyHeritageWear.com The HIV / HCV Co-Infection Ribbon proudly displayed on a mouse pad. There is no better way to achieve awareness for the meaning of the HIV / HCV Co-Infection Ribbon than to display it on your mouse pad for everyone to see. The mouse pad measures at 9.25 x 7.75, it is machine washable, and the colors will not fade or run. Start gaining awareness today by presenting your HIV / HCV Co-Infection Ribbon mouse pad at work or at home. It is certain to keep your mouse rolling in style all while gaining support and awareness! |
|
Pulmonary Complications of HIV Infection Volume 4 Also With: Bayer Pharmaceutical Division (Primary Contributor) The Pulmonary Clinical Consultant. Diagnosis and Management of acute lung injury in multiple organ dysfunction syndrome. | |
 |
The Guide to Living with HIV Infection: Developed at the Johns Hopkins AIDS Clinic (A Johns Hopkins Press Health Book) by John G. Bartlett MD (Author), Ann K. Finkbeiner (Author) The Guide to Living with HIV Infection is the most complete source of medical, emotional, social, and practical advice available for those infected with HIV and their loved ones. Developed at the Johns Hopkins AIDS Clinic, the guide provides essential information for making decisions about treatment and testing in a world transformed by new research and pharmacotherapy. In this thoroughly updated sixth edition, Dr. John Bartlett and Ann K. Finkbeiner address the latest information about risks of transmission, viral mutations that confer drug resistance, and new, rapid, HIV testing. They offer guidelines for Highly Active Antiretroviral Therapy (HAART), a therapy protocol that has dramatically increased life expectancy for HIV-positive people. They describe how to follow HAART and... |
 |
Ellagic Insurance Formula Acid (180 capsules) by The Wolfe Clinic Ellagic Acid is a compound found in red raspberries. This unique nutraceutical supplement combines therapeutic levels of polyphenols from plants: ellagitannins (Ellagic acid) from raspberries, pomegranates and terminalia chebula; oligomeric proanthocyanidins (OPC) from whole grape extract; catechins from green tea and Graviola, together with the antioxidant vitamins A, C, E and the mineral Selenium to create a potent antioxidant formula. The scientific laboratory evidence and clinical medical research supporting the protective effects of these nutrients in multiple areas of health concern are reviewed in "Chemopreventive Properties of Phytochemicals " including their potent actions against the two most feared killers of our time, Cardiovascular Disease and Cancer. Ellagic acid causes... |
|
Nutrition & Metabolic Disorders in Hiv Infection by Aamic | |
 |
Healing HIV: How To Rebuild Your Immune System by Jon D., M.D. Kaiser (Author), Jon D. Kaiser (Author) |
 |
The First Year: HIV: An Essential Guide for the Newly Diagnosed (First Year, The) by Brett Grodeck (Author), M.D. Daniel S. Berger (Foreword) This supportive resource explores the next generation of HIV/AIDS drugs and also includes new research on HIV and crystal meth, as well as new insights for the hardest hit population — African Americans. |
|
The Family Physician's Guide to HIV infection and AIDS: Videotape parts 1 & 2 The American Academy of Family Physicians. CME videotape c1990. |
| © 2009 BrightSurf.com |